Eaton Vance Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Eaton Vance Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,000	Closed	-$67K	–	2926
2021 Q3	$67K	Sell	11,000 -40,900	-79%	-$255K	﹤0.01%	1489
2021 Q2	$427K	Buy	51,900 +14,000	+37%	+$119K	﹤0.01%	1379
2021 Q1	$339K	Buy	37,900 +7,400	+24%	+$84.8K	﹤0.01%	1366
2020 Q4	$352K	Buy	30,500 +12,900	+73%	+$150K	﹤0.01%	1299
2020 Q3	$183K	Buy	+17,600	New	+$216K	﹤0.01%	1299
2018 Q1	–	Sell	-12,900	Closed	-$323K	–	1144
2017 Q4	$323K	Buy	12,900 +3,500	+37%	+$85.7K	﹤0.01%	1036
2017 Q3	$227K	Buy	+9,400	New	+$221K	﹤0.01%	1066

Eaton Vance Management's FLXN Position: Q4 2021 in Review

Eaton Vance Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 11,000 shares — an estimated $67K sold.

Eaton Vance Management first reported a position in FLXN in Q3 2017 and held it in 7 quarters. The position peaked at $427K in Q2 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Eaton Vance Management reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Eaton Vance Management sold 11,000 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $67K.
Eaton Vance Management first reported a position in Flexion Therapeutics, Inc. in Q3 2017 and held it in 7 quarters.
Eaton Vance Management's Flexion Therapeutics, Inc. position peaked at $427K in Q2 2021.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.